Werewolf Therapeutics, Inc. HOWL 深 沪
等待开盘 05-19 09:30:00 美东时间
0.5014
-0.014
-2.66%
华盛通- 最 高0.55
- 今 开0.52
- 成交量 21.96万股
- 最 低 0.50
- 昨 收 0.5151
- 总市值 2436.64万
- 52周最高 2.38
- 市盈率 静 --
- 换手率 0.45%
- 52周最低 0.50
- 委 比 28.57%
- 总股本 4859.68万
- 历史最高 23.99
- 量 比 0.57
- 振 幅 9.71%
- 历史最低 0.50
- 每 手 1
- 风险率 0.37%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Werewolf Therapeutics Q1 EPS $(0.28), Inline
Werewolf Therapeutics (NASDAQ:HOWL) reported quarterly losses of $(0.28) per share which met the analyst consensus estimate. This is a 30 percent increase over losses of $(0.40) per share from the same period last year.
05-08 04:45
Earnings Scheduled For March 27, 2026
Companies Reporting Before The Bell • Instil Bio (NASDAQ:TIL) is expected to re...
03-27 19:11
Werewolf Therapeutics Q4 net loss narrows as expenses fall
Werewolf Therapeutics Q4 net loss narrows as expenses fall Overview US biopharmaceutical firm's Q4 net loss narrowed yr/yr Operating expenses for Q4 declined compared to prior year Company initiated process to explore strategic alternatives including sale of assets or merger Outlook Werewolf Therape
03-27 19:10
Werewolf Therapeutics Q4 EPS $(0.20) Beats $(0.35) Estimate
Werewolf Therapeutics (NASDAQ:HOWL) reported quarterly losses of $(0.20) per share which beat the analyst consensus estimate of $(0.35) by 43.18 percent. This is a 56.52 percent increase over losses of $(0.46) per share
03-27 19:02
Werewolf Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Updates
Werewolf Therapeutics announced a strategic review to maximize shareholder value, exploring options like sale, merger, or partnerships, with Piper Sandler as advisor. Q4 and 2025 financials showed cash of $57.1M, reduced R&D and G&A expenses, and narrowed net loss to $8.4M from $20.4M. Strategic alternatives are under consideration without a set timeline.
03-27 11:00
Werewolf Therapeutics Begins Strategic Alternatives Review Process
Werewolf Therapeutics ( ($HOWL) ) has shared an announcement. On February 24, 2...
02-25 07:22
Werewolf Therapeutics shares are trading higher after the company announced plans to explore strategic alternatives.
Werewolf Therapeutics shares are trading higher after the company announced pla...
02-25 05:38
Werewolf Therapeutics Mulls Strategic Options
Werewolf Therapeutics, Inc. (Nasdaq: HOWL) (the "Company" or "Werewolf"), an innovative biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the
02-25 05:12
Werewolf Therapeutics Receives Nasdaq Minimum Bid Price Notice
An announcement from Werewolf Therapeutics ( ($HOWL) ) is now available. On Feb...
02-07 06:00
Werewolf Therapeutics Faces Nasdaq Delisting Risk Over Minimum Bid Price Compliance
Werewolf Therapeutics Faces Nasdaq Delisting Risk Over Minimum Bid Price Compliance Werewolf Therapeutics Inc. has received a deficiency letter from the Nasdaq Stock Market, notifying the company that its common stock has closed below the $1.00 minimum bid price required for continued listing on the
02-07 05:41
